Skip to main content

Table 2 Growth factor and cytokine profiling in systemic sclerosis and control plasma samples

From: Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis

Biologic function

 

Healthy control samples

SSc samples

P value

Innate immunity

IFNα2

20.16 (14.47 to 29.72)

28.86 (18.41 to 39.83)

0.33

 

IL-1α

2.51 (2.51 to 5.78)

2.51 (2.51 to 17.91)

0.37

 

IL-1B

1.65 (1.65 to 1.65)

1.65 (1.65 to 1.72)

0.40

 

IL-1RA

34.52 (25.15 to 44.60)

57.36 (35.85 to 83.9)

0.03

 

IL-6

2.66 (2.66 to 2.66)

2.66 (2.66 to 2.69)

0.29

 

IL-12p40

4.77 (4.77 to 5.63)

12.92 (4.77 to 28.25)

0.07

 

IL-12p70

3.78 (2.97 to 5.64)

4.73 (3.46 to 7.78)

0.34

 

IL-15

2.45 (2.45 to 2.45)

2.45 (2.45 to 2.76)

0.29

 

IP-10

297 (189.75 to 448)

396 (317.5 to 544.5)

0.27

 

TNFα

4.38 (3.98 to 6)

6.98 (4.98 to 8.84)

0.04

Adaptive immunity

IFNγ

3.7 (2.99 to 4.49)

4.89 (3.26 to 6.82)

0.38

 

IL-2

1.47 (1.47 to 1.47)

1.47 (1.47 to 2.14)

0.29

 

IL-3

0.36 (0.34 to 0.54)

0.57 (0.34 to 0.82)

0.54

 

IL-4

2.83 (2.83 to 2.83)

2.83 (2.83 to 3.65)

0.20

 

IL-5

1.93 (1.93 to 1.93)

1.93 (1.93 to 1.93)

0.52

 

IL-7

2.28 (1.78 to 2.89)

2.66 (2.14 to 3.85)

0.47

 

IL-9

1.24 (1.24 to 1.24)

1.24 (1.24 to 1.24)

0.40

 

IL-10

1.55 (1.03 to 2.91)

2.86 (1.48 to 5.18)

0.13

 

IL-13

1.65 (1.65 to 1.65)

1.65 (1.65 to 1.65)

0.40

 

IL-17α

2.33 (1.75 to 2.38)

2.49 (1.61 to 3.38)

0.38

 

sCD40L

9,800.01 (9,800.01 to 9,800.01)

9,800.01 (9,800.01 to 9,800.01)

0.87

 

TNFβ

2.34 (2.34 to 2.76)

2.34 (2.34 to 3.26)

0.49

Chemokines

Eotaxin

95.3 (67.43 to 129.75)

97.64 (76.3 to 132.5)

0.87

 

Fractalkine

50.87 (41.87 to 57.36)

62.72 (49.39 to 72.85)

0.21

 

GRO

627.5 (477.25 to 655)

556 (383.5 to 709)

0.52

 

IL-8

3.11 (1.97 to 4.32)

3.29 (2.78 to 4.07)

0.58

 

MCP-1

236.5 (217.5 to 240.5)

230 (157.5 to 274)

0.83

 

MCP-3

8.84 (5.73 to 13.41)

14.68 (8.63 to 19.76)

0.06

 

MDC

718 (686.75 to 785.5)

696 (624 to 835)

0.71

 

MIP-1α

1.6 (1.6 to 2.03)

1.77 (1.6 to 3.99)

0.24

 

MIP-1β

18.47 (16.15 to 24.73)

21.92 (17.75 to 27.85)

0.52

 

RANTES

1,869 (1,723.5 to 2,090.5)

1,473 (1,234 to 1,626)

0.01

Growth factors

EGF

49.36 (38.36 to 144.75)

63.8 (47.29 to 128)

0.83

 

Flt-3 L

5.07 (5.07 to 5.07)

5.07 (5.07 to 5.59)

0.29

 

GCSF

35.64 (33.17 to 39.41)

43.21 (34.88 to 54.04)

0.21

 

GMCSF

7.9 (6.04 to 10.71)

12.84 (9.15 to 20.06)

0.05

 

PDGF-AA

1,518.5 (889 to 1,852)

1,300 (825.5 to 1,601.5)

0.49

 

PDFG-BB

4,137 (2,686.5 to 5,063.75)

4,573 (3,646 to 5,609.5)

0.43

 

TGFα

0.41 (0.41 to 0.41)

0.41 (0.41 to 0.41)

0.40

 

FGF-2

59.52 (48.78 to 80.7)

78.75 (57.53 to 95.77)

0.12

 

VEGF

71.78 (50.92 to 91.04)

130 (81.12 to 202)

0.08

  1. Data presented as median concentration (pg/ml) (25th to 75th percentile). Permutation analysis: significance analysis of microarrays for Excel, Wilcoxon rank-sum test. Significant results are in bold, taken as P <0.05. EGF, epidermal growth factor; FGF, fibroblast growth factor; Flt, FMS-like tyrosine kinase; GCSF, granulocyte colony-stimulating factor; GMCSF, granulocyte–macrophage colony-stimulating factor; GRO, growth regulated oncogene; IFN, interferon; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; IP-10, Interferon gamma induced protein 10; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; PDGF, platelet-derived growth factor; RANTES, regulated on activation normal T cell expressed and secreted; SSc, systemic sclerosis; TGF-α, transforming growth factor alpha; TNF-α, tumour necrosis factor alpha; VEGF, vascular endothelial cell growth factor.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us